Edwards Lifesciences Corporation (EW) fundamentals from SEC filings — revenue $6.1B, net margin 17.7%, diluted EPS $1.83 in FY2025. Revenue, margins, EPS and free cash flow, year by year.
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $5.2B | $4.5B | $5.0B | $5.4B | $6.1B |
| Net income | $1.5B | $1.5B | $1.4B | $4.2B | $1.1B |
| Net margin | 28.7% | 34.1% | 28.0% | 76.8% | 17.7% |
| Diluted EPS | $2.38 | $2.44 | $2.30 | $6.97 | $1.83 |
| Free cash flow | $1.4B | $973.6M | $642.8M | $289.9M | $1.3B |
Figures are as reported to the SEC (EDGAR companyfacts), in the filer's own fiscal years.
Sign in to PortfolioX for the full analysis — ten years of history, segment and geographic breakdowns, valuation multiples, analyst estimates and filings. · PortfolioX home